Dr. Gieschen on Standard Approaches to Radiation Therapy in Prostate Cancer

Video

In Partnership With:

Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses standard approaches to radiation therapy in prostate cancer.

Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses standard approaches to radiation therapy in prostate cancer.

There are many approaches in terms of radiation delivery, explains Gieschen. Standard external beam treatment is used over a longer period of time, whereas shorter courses of radiation can be given over a duration of 5.5 weeks. Selecting the right method should be individualized to each patient and the state of their disease, he adds. Patient preferences and expectations should also be factored into a treating physician’s decision.

In prostate cancer, radiation can be combined with androgen deprivation therapy (ADT). This approach is most appropriate in intermediate- and poor-risk populations, explains Gieschen. Patients with low-risk disease do not need the addition of ADT. Conversely, ADT should always be incorporated into the treatment course of a patient with high-risk disease if there are no contraindications that state otherwise.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD